ArticleRenal failure2025
The level and clinical significance of serum soluble M-type phospholipase A2 receptor in patients with primary membranous nephropathy.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary membranous nephropathy (PMN) is a kidney-specific autoimmune glomerular disease, M-type phospholipase A2 receptor (PLA2R1) is the target antigen. However, the level of PLA2R1 in PMN patients serum remains unclear. Enzyme-linked immunosorbent assay (ELISA) was used to measure PLA2R1, aiming to clarify the diagnostic value and potential clinical significance of PLA2R1 in PMN patients. A total of 115 PMN patients and 35 healthy controls (HCs) from Peking University Third Hospital were enrolled in this study. Spearman correlation, multivariable logistic regression, and receiver operating characteristic (ROC) curve were used for analysis. The PLA2R1 level were significantly higher in PMN patients 67.69 (33.19, 115.14) ng/mL compared to HCs 39.08 (24.74, 50.26) ng/mL (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.